News | February 28, 2023
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Subscribe To Our Newsletter & Stay Updated
